Free Trial
NASDAQ:AKUS

Akouos (AKUS) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$13.29
$13.29
50-Day Range
$13.29
$13.29
52-Week Range
$2.32
$13.60
Volume
440 shs
Average Volume
344,411 shs
Market Capitalization
$490.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AKUS stock logo

About Akouos Stock (NASDAQ:AKUS)

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.

AKUS Stock News Headlines

NOVARTIS AG's Net Worth
Joshua Makower's Net Worth
A scientific breakthrough in energy technology?
At first glance, it looks like some ordinary “orange” powder… But in reality, it is a scientific breakthrough in energy technology. One that could wipe out fossil fuel, coal, and even the “glorified” renewable energy in just a few years. And right now, governments, institutions, and the elites are jumping on this resource at record pace to the point where we’re starting to run out. The question is… Why are the top 1% piling in this much? And more importantly, what will be the implications of this act by the elites on YOU and of course, the stock market?
William W. Backus Hospital
A scientific breakthrough in energy technology?
At first glance, it looks like some ordinary “orange” powder… But in reality, it is a scientific breakthrough in energy technology. One that could wipe out fossil fuel, coal, and even the “glorified” renewable energy in just a few years. And right now, governments, institutions, and the elites are jumping on this resource at record pace to the point where we’re starting to run out. The question is… Why are the top 1% piling in this much? And more importantly, what will be the implications of this act by the elites on YOU and of course, the stock market?
See More Headlines
Receive AKUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akouos and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
7/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AKUS
Fax
N/A
Employees
103
Year Founded
N/A

Profitability

Net Income
$-86,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.90 per share

Miscellaneous

Free Float
35,163,000
Market Cap
$490.88 million
Optionable
Not Optionable
Beta
-0.55
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Emmanuel Simons M.B.A. (Age 39)
    Ph.D., Co- Founder, Pres, CEO & Director
    Comp: $790.72k
  • Dr. Michael John McKenna M.D. (Age 65)
    Co-Founder, Chief Medical Officer & Member of Scientific Advisory Board
    Comp: $539.35k
  • Ms. Jennifer Anne Wellman M.S. (Age 44)
    Chief Operating Officer
    Comp: $568.67k
  • Dr. Luk H. Vandenberghe M.D.
    Ph.D., Founder & Member of Scientific Advisory Board
  • Mr. William F. Sewell Ph.D.
    Founder & Member of Scientific Advisory Board
  • Mr. Richard Smith M.D.
    Founder & Member of Scientific Advisory Board
  • Ms. Sachiyo Minegishi (Age 44)
    CFO, Treasurer, Assistant Sec. & Principal Accounting Officer
  • Ms. Stacy Price
    Chief Technical Officer
  • Dr. Aaron Tward M.D.
    Ph.D., Chief Scientific Officer
  • Dr. Karoline K. Shair
    Sr. VP, Gen. Counsel, Chief Legal Officer & Corp. Sec.

AKUS Stock Analysis - Frequently Asked Questions

How were Akouos' earnings last quarter?

Akouos, Inc. (NASDAQ:AKUS) issued its quarterly earnings results on Friday, November, 12th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.04.

When did Akouos IPO?

Akouos (AKUS) raised $124 million in an initial public offering on Friday, June 26th 2020. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler acted as the underwriters for the IPO and BTIG was co-manager.

What other stocks do shareholders of Akouos own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Akouos investors own include NVIDIA (NVDA), QUALCOMM (QCOM), RTX (RTX), CVS Health (CVS), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

This page (NASDAQ:AKUS) was last updated on 7/21/2024 by MarketBeat.com Staff

From Our Partners